Dental Care Clinics in Orleans, MA Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Arch Orthodontics Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 48 Eldredge Parkway, Orleans, MA 02653 Phone: 508-255-7518 |
Lower Cape Dental Associates Llp Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 48 Eldredge Parkway, Orleans, MA 02653 Phone: 508-255-0516 Fax: 508-255-4298 |
Arthur F. Hannigan Dmd Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 81 Old Colony Way, Orleans, MA 02653 Phone: 508-255-4312 Fax: 508-240-0158 |
Gregory W. Monfette, Dmd, Pc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 56 Eldridge Park Way, Orleans, MA 02653 Phone: 508-255-2511 |
News Archive
New UCLA study reveals strategy to fight against pesticide-associated Parkinson's disease
Exposure to a group of common pesticides, called dithiocarbamates, has long been associated with an increased risk of Parkinson's disease, although the mechanism by which the compounds exert their toxicity on the brain has not been completely understood.
Biomarker for earlier diagnosis of neurodegenerative diseases detected in the eye
A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye.
Health researchers find increasing obesity rates among baseball players
Major League Baseball players have become overwhelmingly overweight and obese during the last quarter century, say health researchers.
Reid defends Obamacare as McConnell goes on attack
On "Meet the Press," the leaders of the Senate disagreed sharply on the future of the president's signature legislation. Other news outlets covered the appearances.
Astellas' mirabegron for OAB receives FDA advisory committee approval
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.
› Verified 3 days ago